Pan-Disaccharidase Supplements: There Are No FDA-Approved Products
I cannot provide examples of pan-disaccharidase supplements because none exist as FDA-approved medications. Unlike pancreatic enzyme replacement therapy (PERT), which has multiple FDA-approved formulations for treating exocrine pancreatic insufficiency, there are currently no regulated pharmaceutical products specifically approved for treating pan-disaccharidase deficiency 1.
Critical Distinction: Supplements vs. Medications
The evidence explicitly warns against over-the-counter enzyme products. Over-the-counter commercially available enzyme replacements should not be used, as they are classified as dietary supplements only—their dosing and efficacy are neither standardized nor regulated, and thus utility and safety are unknown 2.
This creates a significant clinical challenge: while disaccharidase deficiency is common in adults with chronic GI symptoms (affecting approximately 40% of patients with gas and bloating) 3, and pan-disaccharidase deficiency (deficiency in 3 or more enzymes) occurs in about 10% of these patients 3, there are no regulated treatment options beyond dietary restriction.
Current Treatment Approach
For patients with confirmed pan-disaccharidase deficiency:
Primary Strategy: Dietary Restriction
- Eliminate or reduce intake of problematic carbohydrates based on which enzymes are deficient
- Pan-deficient patients require restriction of lactose, sucrose, maltose, and isomaltose-containing foods
- This is more restrictive than low-FODMAP diets and requires careful nutritional counseling
Secondary Consideration: Unregulated Supplements
While enzyme replacement therapy has been mentioned as potentially effective 1, the lack of FDA-approved products means:
- Any available products are unregulated dietary supplements
- Dosing is not standardized
- Efficacy and safety data are limited or absent
- Quality control is not guaranteed
Clinical Pitfalls
Do not confuse this with PERT for pancreatic insufficiency. The FDA-approved PERT products (Creon, Zenpep, Pancreaze, Pertzye, Viokace, Relizorb) contain lipase, amylase, and proteases—not the specific disaccharidases (lactase, sucrase, maltase, isomaltase) needed for carbohydrate digestion 2.
Testing is essential before treatment. Disaccharidase deficiency significantly overlaps with IBS symptoms, and patients who fail low-FODMAP diets should be evaluated with duodenal biopsies (gold standard) or breath testing 1.
The Evidence Gap
Pan-disaccharidase deficiency represents an underdiagnosed and undertreated condition 1. Patients with pan-deficiency have a distinct phenotype with more weight loss than single-enzyme deficiency 3, 1, yet no pharmaceutical-grade enzyme replacement exists. This contrasts sharply with pancreatic insufficiency, where failure to provide adequate enzyme replacement results in malnutrition, poor quality of life, and increased mortality 2.